Telehealth & Digital Health

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.

Omeros begins sales of YARTEMLEA, the first and only approved therapy for TA-TMA, a fatal complication of stem cell transplants, shifting the paradigm.

Myriad Genetics is launching a new cancer test that promises to detect recurrence earlier than ever. But can it win in a competitive market?

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

As US organ donor registrations fall, Southern Legacy of Life achieves its second-best year, saving hundreds through strategic community engagement.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

As consolidation reshapes healthcare, Integrated Dermatology's new CMO appointment signals a strategic move to blend clinical leadership with corporate growth.

A new partnership brings vital mental health screenings and support directly to NICU parents, addressing a hidden crisis with long-term benefits for families.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

A new FDA-cleared test detects RSV, Flu A/B, and COVID from a single swab, offering a powerful diagnostic tool for families, especially for infants.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

Ossium Health's groundbreaking study using banked bone marrow from deceased donors could solve the critical shortage of transplant matches for patients.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

SPR Therapeutics unveils 12-month data at NANS 2026, showing its temporary SPRINT PNS system provides durable pain relief without a permanent implant.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

A new AI system scans IDs to identify high-risk individuals in real-time, but raises questions about the balance between hospital safety and privacy.